How your cancer is identified
There are many ways to diagnose cancer. Utilizing various methods can be important to creating a comprehensive understanding of your cancer and to help expose cancer in challenging situations. Your provider may order one or more method to determine your cancer's diagnosis and prognosis.
Download this simple guide to help you better understand your solid tumor cancer to and assist with communicating with your care team.
Tumor Profiling
Identifying a cancer’s unique hallmarks
Tumor profiling [often called genomic profiling, molecular profiling, or biomarker testing] is a laboratory test to check for gene mutations or other alterations that makeup the tumor biology and underlie the cancer growth. This information can help physicians build a personalized treatment plan based on the tumor profile.
Each patient’s cancer has a unique genetic barcode. Blood cancers (like leukemia and lymphoma) as well as solid tumor cancers (such as breast and colon cancer) can carry unique mutations. While many patients could have the same official diagnosis, such as non-small cell lung cancer (NSCLC) or acute myeloid leukemia (AML), there are often underlying genetic variations in the cancer cells that make one patient’s lung cancer or leukemia different from the next patient’s.
The contribution of cancer research and clinical trials continuously advance the cancer landscape to be able to identify a cancer’s unique biological drivers and initiate the right treatment for the right patient. This is what is known as precision medicine.
Having tumor profiling, also known as biomarker testing, is a detailed and sensitive laboratory analysis of the cancer cells. The purpose of this testing exposes specific biomarker mutations, and identify targeted therapies matched to any found mutations. Tumor profiling can help guide and identify the most effective treatment plan. NeoGenomics Laboratories provides genetic profiling of a patient’s cancer to identify its unique biological drivers and weaknesses.
Studies have shown that over 60% of patients have a detectable abnormality, with the majority being actionable and associated with a targeted therapy.
Consult with your Health Care Provider to determine if biomarker testing is best for you.
We’re Here to Help
Looking for additional information on NeoGenomics testing capabilities? Our Patient Support team is on hand to help.
Call us at 866.776.5907, ext. 9, Fax us at 760.670.2722
or